Literature DB >> 17371958

15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors.

Cinzia Fionda1, Filomena Nappi, Mario Piccoli, Luigi Frati, Angela Santoni, Marco Cippitelli.   

Abstract

Receptor activator of NF-kappaB ligand (RANKL) and its receptor RANK are cell surface proteins abundantly expressed in bone and lymphoid tissues, whose interaction triggers different signaling pathways leading to activation and differentiation of osteoclasts, pivotal actors of the normal bone remodeling cycle. Moreover, RANKL may act as an immunomodulator, representing an important dendritic cell survival factor produced by activated T cells. A large body of research has shown that not only does the RANKL/RANK system regulate the physiology of bone development but also plays an important pathological role in bone destruction mediated by inflammatory disorders or bone metastatic tumors. 15-Deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)) is a cyclopentenone-type PG endowed with anti-inflammatory properties and produced by different cells, including those of the immune system. Although 15d-PGJ(2) has been studied as a natural ligand of the peroxisome proliferator-activated receptor-gamma nuclear receptor, relevant peroxisome proliferator-activated receptor-gamma-independent actions mediated by this prostanoid have been described. In this study, we describe the effect of 15d-PGJ(2) on the expression of the rankl gene in T lymphocytes. We show that 15d-PGJ(2) inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety. Our data also indicate that 15d-PGJ(2) represses rankl activation by interfering with the expression and/or activity of the transcription factors NF-kappaB, early growth response-2, and early growth response-3, whose altered balancing and transactivation may contribute for the repression of this gene. These results place rankl as a novel molecular target for the different immunoregulatory activities mediated by 15d-PGJ(2). The physiological and pharmacological implications of these observations are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371958     DOI: 10.4049/jimmunol.178.7.4039

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Authors:  Elisabetta Vulpis; Francesca Cecere; Rosa Molfetta; Alessandra Soriani; Cinzia Fionda; Giovanna Peruzzi; Giulio Caracciolo; Sara Palchetti; Laura Masuelli; Lucilla Simonelli; Ugo D'Oro; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rossella Paolini; Marco Cippitelli; Angela Santoni; Alessandra Zingoni
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

2.  Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region.

Authors:  Kathleen A Bishop; Heidi M Coy; Robert D Nerenz; Mark B Meyer; J Wesley Pike
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

Review 3.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

4.  Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice.

Authors:  L A Mitchell; F T Lauer; S W Burchiel; J D McDonald
Journal:  Nat Nanotechnol       Date:  2009-06-14       Impact factor: 39.213

5.  Effects of rheumatoid arthritis associated transcriptional changes on osteoclast differentiation network in the synovium.

Authors:  Shilpa Harshan; Poulami Dey; Srivatsan Ragunathan
Journal:  PeerJ       Date:  2018-10-11       Impact factor: 2.984

6.  Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers.

Authors:  Kathleen A Bishop; Xiaohua Wang; Heidi M Coy; Mark B Meyer; Jenny E Gumperz; J Wesley Pike
Journal:  J Cell Biochem       Date:  2015-02       Impact factor: 4.480

7.  NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.

Authors:  Tetsuo Kubota; Machiko Hoshino; Kazuhiro Aoki; Keiichi Ohya; Yukiko Komano; Toshihiro Nanki; Nobuyuki Miyasaka; Kazuo Umezawa
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  To Live or to Die: Prosurvival Activity of PPARgamma in Cancers.

Authors:  Y Lynn Wang; Qi Miao
Journal:  PPAR Res       Date:  2008       Impact factor: 4.385

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.